Recursion Appoints Najat Khan, PhD, as Chief R&D Officer and Chief Commercial Officer
Retrieved on:
Martedì, Aprile 16, 2024
University, Cancer, Organic chemistry, University of Pennsylvania, AI, Merck & Co., Johnson & Johnson, Data science, Najat, Doctor of Philosophy, Research, Artificial intelligence, Entrepreneurship, Science, Patient, Chemistry, Biology, Ethics, Colgate University, Drug discovery, Committee, Economics, Computational chemistry, Pharmaceutical industry
SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
Key Points:
- SALT LAKE CITY, April 16, 2024 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a clinical stage TechBio company leading the space by decoding biology to industrialize drug discovery and development, announced Najat Khan, PhD, will be its Chief R&D Officer and Chief Commercial Officer.
- Dr. Khan will lead Recursion’s research and development, and build its emerging commercial capabilities.
- “Najat brings a unique blend of leadership in biological, chemical, and medical sciences, data science, and business,” said Chris Gibson, Co-Founder and CEO of Recursion.
- Najat is the founder and co-chair of the Data Science in Industry Roundtable (DISRUPT) – a cross industry forum dedicated to driving impact through Data Science.